The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
Open accessAbstract
Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for the detection of EGFR mutations. This systematic review and meta-analysis was designed to assess the diagnostic performance of cfDNA, compared with tissues. True-positive (TP), false-positive (FP), false-negative (FN), and true-negative (TN) values were extracted or calculated for each study. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated. A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall diagnostic performance. 20 eligible studies involving 2012 cases were included in this meta-analysis. The pooled sensitivity, specificity, PLR, NLR, and DOR were 0.674 (95%CI: 0.517-0.800), 0.935 (95%CI: 0.888-0.963), 10.307 (95%CI: 6.167-17.227), 0.348 (95%CI: 0.226-0.537), and 29.582 (95%CI: 4.582-60.012), respectively. The AUC was 0.93 (95% CI: 0.90-0.95). The meta-analysis suggests that detection of EGFR mutation by cfDNA is of adequate diagnostic accuracy and cfDNA analysis could be a promising screening test for NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR mutations detected in plasma and urine have been shown to be concordant with those identified by tumor biopsy”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Noninvasive genotyping of cell-free plasma DNA (cfDNA) represents an attractive alternative for detection of EGFR T790M, noting that plasma genotyping for EGFR-sensitizing mutations is an established alternative in Europe when tumor genotyping is not feasible.19”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Deeks, J. J., Macaskill, P., & Irwig, L. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.01.016 · Cited by 2,910
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The diagnostic odds ratio: a single indicator of test performance
Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J., & Bossuyt, P. M. M. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00177-x · Cited by 2,261
Cited by
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0388-cp · Cited by 936
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
“Diagnostic Analysis Using the diagnostic analysis set (n = 216) with central tissue genotype as reference, sensitivity of plasma genotyping for the known sensitizing mutation was 82% for exon 19 deletions (112 of 136; 95% CI, 75% to 88%) and 86% for L858R (63 of 73; 95%CI, 76% to 93%; Table 1, Appendix Fig A2A, online…”
ResultLindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.001 · Cited by 645
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Biomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.56 · Cited by 556
Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 493
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Thomas, D., Rathinavel, A. K., & Radhakrishnan, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188464 · Cited by 372
How liquid biopsies can change clinical practice in oncology
Siravegna, G., Mussolin, B., Venesio, T., Marsoni, S., Seoane, J., Dive, C., Papadopoulos, N., Kopetz, S., Corcoran, R. B., Siu, L. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz227 · Cited by 358
Lindeman, N. I., Cagle, P. T., Aisner, D. L., Arcila, M. E., Beasley, M. B., Bernicker, E. H., Colasacco, C., Dacic, S., Hirsch, F. R., Kerr, K., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.004 · Cited by 346
Paweletz, C. P., Sacher, A. G., Raymond, C. K., Alden, R. S., O'Connell, A., Mach, S. L., Kuang, Y., Gandhi, L., Kirschmeier, P., English, J. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1627-t · Cited by 244
“In this pilot study, sensitivity of plasma NGS was 77%, comparable to most plasma genotyping assays whichhave reported sensitivity in the rangeof 70% (24).”
Zheng, D., Ye, X., Zhang, M. Z., Sun, Y., Wang, J. Y., Ni, J., Zhang, H. P., Zhang, L., Luo, J., Zhang, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20913 · Cited by 226
Self-citationFigueroa, J. M., Skog, J., Akers, J., Li, H., Komotar, R., Jensen, R., Ringel, F., Yang, I., Kalkanis, S., Thompson, R., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox085 · Cited by 204
Marchetti, A., Palma, J. F., Felicioni, L., De Pas, T. M., Chiari, R., Del Grammastro, M., Filice, G., Ludovini, V., Brandes, A., Chella, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000643 · Cited by 182
Reck, M., Hagiwara, K., Han, B., Tjulandin, S., Grohé, C., Yokoi, T., Morabito, A., Novello, S., Arriola, E., Molinier, O., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.036 · Cited by 174
Molecular biomarkers for lung adenocarcinoma
Calvayrac, O., Pradines, A., Pons, E., Mazières, J., & Guibert, N. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 158
Sherwood, J. L., Corcoran, C., Brown, H. J., Sharpe, A. D., Musilová, M., & Kohlmann, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150197 · Cited by 160
“Currently tumour tissue remains the recommended gold standard sample type due to the relatively low detection rate in ctDNA when compared to tumour tissue[3,24].”
BackgroundChae, Y. K., & Oh, M. S. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.022 · Cited by 150
Normanno, N., Denis, M. G., Thress, K. S., Ratcliffe, M., & Reck, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13915 · Cited by 151
“Meta-analyses have indicated that detection of EGFR mutations using ctDNA may be effective for diagnostic purposes [22-24].”
Liquid biopsy for cancer screening, patient stratification and monitoring
Brock, G., Castellanos-Rizaldos, E., Hu, L., Coticchia, C. M., & Skog, J. (2018) · Translational Cancer Research · doi:10.21037/4546 · Cited by 154
“There is currently an intensive research effort to understand the utility of cfDNA in various clinical fields such as cancer research (38,39), non-invasive prenatal testing (40) and transplant rejection diagnostics (41).”
BackgroundGuibert, N. M., Pradines, A., Favre, G., & Mazières, J. (2020) · European Respiratory Review · doi:10.1183/16000617.0052-2019 · Cited by 151
Tissue and Blood Biomarkers in Lung Cancer: A Review
Duffy, M. J., & O'Byrne, K. J. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.05.001 · Cited by 135
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring
Pérez-Callejo, D., Romero, A., Provencio, M., & Torrente, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.07 · Cited by 121
“Finally, two meta-analyses exploring the diagnostic value of cfDNA for the detection of EGFR mutation status have been published (59,60).”
BackgroundMayo‐de‐las‐Casas, C., Jordana‐Ariza, N., Garzón‐Ibáñez, M., Balada‐Bel, A., Bertrán-Alamillo, J., Viteri, S., Reguart, N., Muñoz-Quintana, M. A., Barragán, P. L., Camps, C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx288 · Cited by 103
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
Wang, S., Song, Y., Yan, F., & Liu, D. (2016) · Frontiers of Medicine · doi:10.1007/s11684-016-0488-1 · Cited by 98
EGFR mutations in lung cancer: from tissue testing to liquid biopsy
Fenizia, F., Luca, A. D., Pasquale, R., Sacco, A., Forgione, L., Lambiase, M., Iannaccone, A., Chicchinelli, N., Franco, R., Rossi, A., et al. (2015) · Future Oncology · doi:10.2217/fon.15.23 · Cited by 99
Wang, W., Song, Z., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.978 · Cited by 104
“Moreover, mutation detection in plasma has shown promise in terms of accessibility, convenience, and practicality compared with analysis of isolated circulating tumor cells [18, 19].”
BackgroundPassiglia, F., Rizzo, S., Maïo, M. D., Galvano, A., Badalamenti, G., Listì, A., Gulotta, L., Castiglia, M., Fulfaro, F., Bazan, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30780-4 · Cited by 100
Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
Ai, B., Liu, H., Huang, Y., & Peng, P. (2016) · Oncotarget · doi:10.18632/oncotarget.10069 · Cited by 93
“Two recent metaanalyses demonstrated that cfDNA was a highly specific and effective biomarker to measure EGFR mutation status in NSCLC [17, 18].”
BackgroundNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
Sun, W., Yuan, X., Tian, Y., Wu, H. K., Xu, H., Hu, G., & Wu, K. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0193-6 · Cited by 87
Lee, J. S., Hur, J. Y., Kim, I. A., Kim, H. J., Choi, C., Lee, J. C., Kim, W. S., & Lee, K. Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-5138-3 · Cited by 89
“approach for detecting EGFR mutations and has been shown to be effective for diagnosis in meta-analysis [18, 19].”
Are liquid biopsies a surrogate for tissue EGFR testing?
Goldman, J. W., Noor, Z. S., Remón, J., Besse, B., & Rosenfeld, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx706 · Cited by 81
Chen, Y., Ma, Z., Zhong, J., Li, L., Min, L., Xu, L., Li, H., Zhang, J., Wu, W., & Dai, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-25552-z · Cited by 79
Radiomics signature of brain metastasis: prediction of EGFR mutation status
Wang, G., Wang, B., Wang, Z., Li, W., Xiu, J., Liu, Z., & Han, M. (2021) · European Radiology · doi:10.1007/s00330-020-07614-x · Cited by 82
EGFR T790M resistance mutation in non small-cell lung carcinoma
Denis, M. G., Vallée, A., & Théoleyre, S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.039 · Cited by 78
“Recent works have demonstrated that circulating DNA is a powerful source of DNA that can be successfully used to detect activating EGFR mutations [64–66].”
BackgroundCaputo, V., Ciardiello, F., Corte, C. M. D., Martini, G., Troiani, T., & Napolitano, S. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00125 · Cited by 88
Veldore, V. H., Choughule, A. B., Routhu, T., Mandloi, N., Noronha, V., Joshi, A., Dutt, A., Gupta, R. K., Ramprasad, V. L., & Prabhash, K. (2018) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s147841 · Cited by 80
“In spite of this variability, a recent meta-analysis on diagnostic value of plasma cfDNA in place of tissue biopsy demonstrated adequate diagnostic accuracy for plasma cell-free DNAbased EGFR testing as promising screening test for NSCLC patients.(27) So far, the circulating nucleic acid isolation kit from Qiagen has…”
BackgroundResultGilson, P., Merlin, J., & Harlé, A. (2021) · Cancers · doi:10.3390/cancers13071491 · Cited by 73
Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 78
“Considering the high number of reports present in literature, two meta-analysis investigating the diagnostic value of cftDNA for EGFR mutations identification have been published and both included studies with paired tissue and plasma samples (44,45).”
BackgroundResultZhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 74
Herbreteau, G., Vallée, A., Charpentier, S., Normanno, N., Hofman, P. M., & Denis, M. G. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.18 · Cited by 70
“Some of these studies have been included in meta-analyses (51-53).”
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer
Levy, B. P., Hu, Z. I., Cordova, K. N., Close, S. L., Lee, K., & Becker, D. J. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0082 · Cited by 65
What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
Bernabé, R., Hickson, N., Wallace, A. J., & Blackhall, F. H. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.04.022 · Cited by 63
Is tissue still the issue in detecting molecular alterations in lung cancer?
Liam, C. K., Mallawathantri, S., & Fong, K. M. (2020) · Respirology · doi:10.1111/resp.13823 · Cited by 67
Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer
Chen, Y., Ma, Z., Shen, X., Li, L., Zhong, J., Li, M., Xu, L., Li, H., Zhang, J., & Dai, L. (2018) · BioMed Research International · doi:10.1155/2018/5276240 · Cited by 62
“Many of the commonly used serum tumor biomarkers are limited to late-stage disease and have low sensitivity and specificity [32, 33].”
BackgroundLiquid biopsy genotyping in lung cancer: ready for clinical utility?
Huang, W.-L., Chen, Y.-L., Yang, S., Ho, C., Wei, F., Wong, D. T., Su, W., & Lin, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14613 · Cited by 60
“Luo et al [68] identified 20 studies with a total of 2,012 patients and demonstrated that the pooled sensitivity and specificity of cfDNA for detecting EGFR mutation status was 0.674 and 0.935, respectively.”
BackgroundInfluentialScientific Advances in Thoracic Oncology 2016
Soo, R. A., Stone, E. C. A., Cummings, K. M., Jett, J. R., Field, J. K., Groen, H. J. M., Mulshine, J. L., Yatabe, Y., Bubendorf, L., Đačić, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.019 · Cited by 56
Cell-free DNA in cancer: current insights
Fettke, H., Kwan, E. M., & Azad, A. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0413-5 · Cited by 53
Circulating tumor DNA analysis in the era of precision oncology
Said, R., Guibert, N. M., Oxnard, G. R., & Tsimberidou, A. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27418 · Cited by 53
“Although the specificity of these PCR-based platforms allows for the initiation of EGFR-targeted therapy on the basis of positive plasma testing, negative results must be confirmed by tumor tissue genotyping [9].”
BackgroundLiquid Biopsy in Tumor Genetic Diagnosis
Jung, A., & Kirchner, T. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0169 · Cited by 53
Lodrini, M., Graef, J., Thole-Kliesch, T. M., Astrahantseff, K., Sprüssel, A., Grimaldi, M., Peitz, C., Linke, R. B., Hollander, J. F., Lankes, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3716 · Cited by 61
Cons: Can liquid biopsy replace tissue biopsy?—the US experience
Mino-Kenudson, M. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.08.01 · Cited by 53
“Of note, the majority of the studies included in the analysis used single-gene assays (13).”
BackgroundTaus, Á., Camacho, L., Rocha, P., Hardy-Werbin, M., Pijuán, L., Piquer, G., López, E., Dalmases, A., Longarón, R., Clavé, S., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.015 · Cited by 53
Circulating Biomarkers in Non–Small-Cell Lung Cancer: Current Status and Future Challenges
Matikas, A., Syrigos, K. N., & Agelaki, S. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.021 · Cited by 52
Wu, Y.-L. L. C., Lee, V. H.-F., Liam, C. K., Lü, S., Park, K., Srimuninnimit, V., Wang, J., Zhou, C., Appius, A., Button, P., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.004 · Cited by 49
Shah, M. P., & Neal, J. W. (2022) · Drugs · doi:10.1007/s40265-022-01698-z · Cited by 53
“Compared with tissue biopsy, monitoring ctDNA for EGFR mutations has a 67% sensitivity and 94% specificity [104].”
BackgroundPassiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 51
Bartels, S., Persing, S., Hasemeier, B., Schipper, E., Kreipe, H. H., & Lehmann, U. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.05.008 · Cited by 46
Hur, J. Y., Lee, J. S., Kim, I. A., Kim, H. J., Kim, W. S., & Lee, K. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.12.16 · Cited by 48
“As an alternative, plasma EGFR genotyping using tumor-derived cell-free DNA (cfDNA) has been introduced into the clinical practice (4,5).”
MethodHan, J., Choi, J., Kim, J. Y., Han, Y. L., & Lee, G. K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2678-2 · Cited by 50
Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 47
“ARMS is another most commonly used method for EGFR mutation testing both in plasma and tissue [26, 70,76-78, 82-88].”
MethodLiquid Biopsies in Lung Cancer
Kemper, M., Krekeler, C., Menck, K., Lenz, G., Evers, G., Schulze, A. B., & Bleckmann, A. (2023) · Cancers · doi:10.3390/cancers15051430 · Cited by 51
“Multiple meta-analyses have revealed the feasibility of assessing the mutational status via a liquid biopsy [66,67].”
BackgroundDeans, Z. C., Butler, R., Cheetham, M. H., Dequeker, E. M. C., Fairley, J. A., Fenizia, F., Hall, J. A., Keppens, C., Normanno, N., Schuuring, E. M. D., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02571-3 · Cited by 45
“A meta-analysis of 20 studies demonstrated that specificities achieved using cfDNA were comparable to solid tissue genotyping [31].”
MethodPeng, M., Xie, Y., Li, X., Qian, Y., Tu, X., Yao, X., Cheng, F., Xu, F., Kong, D., He, B., et al. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2018-105825 · Cited by 40
Circulating free DNA in the era of precision oncology: Pre‐ and post‐analytical concerns
Lu, J., & Liang, Z. (2016) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2016.12.001 · Cited by 40
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 41
Kujtan, L. A., & Subramanian, J. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1596030 · Cited by 45
Wankhede, D., Grover, S., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14246112 · Cited by 38
“Discordant mutation profiles between plasma and tissue samples, between ctDNA sources, and potential false-positive findings limit the widespread clinical utility of ctDNA in determining MRD [65,83,84].”
BackgroundEmerging platforms using liquid biopsy to detect EGFR mutations in lung cancer
Lin, C., Huang, W.-L., Fang, W., Su, W., & Wong, D. T. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1094379 · Cited by 44
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Normanno, N., Maiello, M. R., Chicchinelli, N., Iannaccone, A., Esposito, C., Cecio, R. D., D’Alessio, A., & Luca, A. D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1272582 · Cited by 37
Dono, M., Luca, G. D., Lastraioli, S., Anselmi, G., Bello, M. G. D., Coco, S., Vanni, I., Grossi, F., Vigani, A., Genova, C., et al. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0082-5 · Cited by 37
“Variable T790M detection rates have been reported ranging between 31 and 66% for BEAMing (beads, emulsion, amplification and magnetics) digital PCR; 18–52% for droplet digital PCR (ddPCR) and 22–30% for common Real Time PCR assays (Luo et al. 2014; Mayo-de-las-Casas et al. 2017).”
Tamminga, M., de Wit, S., Schuuring, E. M. D., Timens, W., Terstappen, L. W. M. M., Hiltermann, T. J. N., & Groen, H. J. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.06 · Cited by 43
Liang, Z., Cheng, Y., Chen, Y., Hu, Y., Liu, W.-P., Lü, Y., Wang, J., Wang, Y., Wu, G., Ying, J., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.008 · Cited by 39
Ma, M., Shi, C., Qian, J., Teng, J., Zhong, H., & Han, B. (2016) · Gene · doi:10.1016/j.gene.2016.06.053 · Cited by 36
Han, J., Choi, J., Kim, J. Y., Han, Y. L., & Lee, G. K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2760-9 · Cited by 33
Zhang, R., Chen, B., Tong, X., Wang, Y., Wang, C., Jin, J., Tian, P., & Li, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s161382 · Cited by 33
“30,31 Therefore, ARMS has exhibited a low sensitivity but a definitely higher specificity.”
Poh, M. E., Liam, C. K., Rajadurai, P., & Chai, C.-S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.122 · Cited by 35
Condello, V., Macerola, E., Ugolini, C., Napoli, L. D., Romei, C., Materazzi, G., Elisei, R., & Basolo, F. (2018) · Head & Neck · doi:10.1002/hed.25155 · Cited by 32
“The concordance of molecular alterations between tissue and corresponding ctDNA would allow the potential development of clinically relevant biomarker blood tests for early detection of cancer, prediction of treatment effect, and response to therapy.(25) It is widely accepted that the molecular analysis on ctDNA is on…”
BackgroundYang, K., Li, J., Zhao, J., Ren, P., Wang, Z., Wei, B., Dong, B., Sun, R., Wang, X., Groen, H. J. M., et al. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01776 · Cited by 33
Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer
Hu, W., Yang, Y., Zhang, L., Yin, J., Huang, J., Huang, L., Gu, H., Jiang, G., & Fang, J. (2017) · Cancer Medicine · doi:10.1002/cam4.980 · Cited by 30
“Detecting cfDNA and EGFR and KRAS mutations in the plasma may help clinicians to assess the survival probability and select precise treatment plan [6, 42].”
BackgroundMinari, R., Mazzaschi, G., Bordi, P., Gnetti, L., Alberti, G., Altimari, A., Gruppioni, E., Sperandi, F., Parisi, C., Guaitoli, G., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.021 · Cited by 31
Circulating DNA in EGFR-mutated lung cancer
Singh, A. P., Li, S., & Cheng, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.07.10 · Cited by 32
“A meta-analysis of 20 studies assessing the performance of ctDNA compared to tissue to detect EGFR mutations in NSCLC, demonstrated a pooled sensitivity of 67% and a pooled specificity of 93% (29).”
BackgroundLiquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
Bertoli, E., Carlo, E. D., Basile, D., Zara, D., Stanzione, B., Schiappacassi, M., Conte, A. D., Spina, M., & Bearz, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310803 · Cited by 40
“Globally, liquid biopsy has good specificity for the EGFR test on plasma, generally greater than 90%, but a lower sensitivity, varying between 50% and 80% depending on the technology employed [45,46].”
MethodLi, Y., Xu, H., Su, S., Ye, J., Chen, J., Jin, X., Lin, Q. D., Zhang, D., Ye, C., & Chen, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183331 · Cited by 31
Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion
Moiseenko, F. V., Volkov, N., Bogdanov, A. A., Dubina, M., & Moiseyenko, V. M. (2017) · F1000Research · doi:10.12688/f1000research.10992.1 · Cited by 35
Vallée, A., Audigier-Valette, C., Herbreteau, G., Merrien, J., Tessonnier, L., Théoleyre, S., & Denis, M. G. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.008 · Cited by 30
Pasquale, R., Fenizia, F., Abate, R. E., Sacco, A., Esposito, C., Forgione, L., Rachiglio, A. M., Bevilacqua, S., Montanino, A., Franco, R., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.45 · Cited by 29
Su, K., Tseng, J., Liao, K.-M., Yang, T., Chen, K., Hsu, K.-H., Yang, P., Yu, S., & Chang, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207001 · Cited by 29
Advances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 39
Yu, H. A., Spira, A. I., Horn, L., Weiss, J. M., West, H., Giaccone, G., Evans, T. L., Kelly, R. J., Desai, B., Krivoshik, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1447 · Cited by 29
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
Vecchiarelli, S., Passiglia, F., D’Incecco, A., Gallo, M., Luca, A. D., Rossi, E., Federica D’Incà, Minuti, G., Landi, L. M., Bennati, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24785 · Cited by 30
Arriola, E., Lario, A. P., García-Gomez, R., Taín, P. D., Constenla, M., Girón, C. G., Márquez, G., Reck, M., & López-Vivanco, G. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1855-y · Cited by 30
“Thus, the pooled sensitivity was higher in two recent meta-analyses of EGFR mutation status concordance between matched tissue/cytology and plasma samples (62–67%) [29, 30].”
ResultThe role of circulating free DNA in the management of NSCLC
Abate, R. E., Pasquale, R., Fenizia, F., Rachiglio, A. M., Roma, C., Bergantino, F., Forgione, L., Lambiase, M., Sacco, A., Piccirillo, M. C., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1548938 · Cited by 29
A rapid MZI-IDA sensor system for EGFR mutation testing in non-small cell lung cancer (NSCLC)
Liu, Q., Lim, S. Y., Soo, R. A., Park, M. K., & Shin, Y. M. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.07.055 · Cited by 29
The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis
Lu, Y., & Li, L. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211043784 · Cited by 27
Chen, C., Douglas, M. P., Ragavan, M. V., Phillips, K. A., & Jansen, J. P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00725-x · Cited by 35
“Previous meta-analyses mostly reported ctDNA performance at the patient level [18, 22, 23] or did not specify the data level [19, 20].”
Kim, C. G., Shim, H. S., Hong, M. H., Cha, Y. J., Heo, S. J., Park, H. S., Kim, J. H., Lee, J. G., Lee, C. Y., Cho, B. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17786 · Cited by 24
“caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.”
BackgroundInfluentialCui, S., Ye, L., Wang, H., Chu, T., Zhao, Y., Gu, A., Xiong, L., Shi, C., & Jiang, L. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.009 · Cited by 24
“e318 sensitivity compared with that using tissue samples.(26-28) Because the DNA in plasma is less than that in tissue, more sensitive assays are needed for identifying EGFR mutations from blood samples.”
BackgroundKim, E. J.-H., Feldman, R. A., & Wistuba, I. I. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.08.001 · Cited by 23
Metadata
- Authors
- Luo, J., Shen, L., & Zheng, D.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Zheng, Di
- Venue
- Scientific Reports
- Published
- 2014-09-09
- Volume
- 4
- Issue
- 1
- Pages
- 6269-6269
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5385820
- OpenAlex
- W1979671400
- Cited by
- 212
- References
- 55
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 6 · 2023: 15 · 2022: 10 · 2021: 16 · 2020: 16 · 2019: 21 · 2018: 33 · 2017: 40 · 2016: 25 · 2015: 20
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- cell-free DNA, EGFR mutation, non-small cell lung cancer, liquid biopsy, diagnostic accuracy, EGFR tyrosine kinase inhibitors, tumor markers
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, DNA, Female, Humans, Lung Neoplasms, Male, Mutation, Quinazolines, ROC Curve, Biomarkers, Tumor, Area Under Curve, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.